Pacific Eye Associates continues to be a leader in clinical research and the development of new therapeutic diagnostic modalities for glaucoma and retinal disease. PEA leads and participates in several clinical trials assessing new therapies for glaucoma, macular degeneration and diabetic retinopathy among other retinal diseases.
Open Clinical Trials – Glaucoma
Comparison of Bimatoprost Sustained Released (SR) to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension (Athena 093)
Description of study: This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication.
- Male or female, 18 years of age or older
- Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that require IOP lowering treatment.
- Willing to withhold your IOP treatments according to the study requirements, and can do so without significant risk.
- No uncontrolled systemic disease
- Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months.
- Females who are pregnant, nursing or planning to be pregnant or who are thinking of becoming pregnant
- Previous or concurrent enrollment in another studies using Bimatoprost SR.
Time commitment: 1 years – 24 appointments visits ranging from every 2 weeks to 6 weeks.
For more information or enrollment questions, please contact our Clinical Research Coordinator, Queennie at 415-923-3482
Long-Term Safety and Efficacy Extension Trial of Bimatoprost Sustained Released (SR) (MAIA 001)
Description of study: This study will evaluate the long-term safety and efficacy of Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.
- Patients who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.
- Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception during the study
- Concurrent or anticipated enrollment in another investigational drug or device study during the present study
- Any condition which would preclude the patient’s ability to comply with study requirements, including completion of the study
- Patients who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092
Time Commitment: 2 years, appointments every 2 months
Enrollment: Not accepting new patients at this time